Advertisement

Dermatitis Herpetiformis

  • Ines Lakos Jukic
  • Branka MarinovićEmail author

Abstract

Dermatitis herpetiformis (DH) is a chronic, subepidermal autoimmune bullous disease associated with gluten sensitivity, and thus it can be defined as a cutaneous manifestation of celiac disease (CD). It was originally described by Louis Adolphus Duhring in 1884. DH is multifactorial disease, with strong association with HLA-DQ2 and HLA-DQ8 antigens, influenced by environmental factors. The diagnosis is based on clinical findings, histopathology, immunofluorescence studies, and serology. The gold standard for diagnosis of DH is finding of granular deposits of IgA within tips of dermal papillae in direct immunofluorescence study. When diagnosis is confirmed, the treatment with gluten-free diet and dapsone is usually recommended. It is necessary to regularly monitor potential side effects of dapsone as well as clinical signs of frequently associated diseases.

Keywords

Dermatitis herpetiformis Celiac disease Transglutaminase Gluten-free diet Dapsone 

Further Reading

  1. Ahrens EM, Meckler RH, Callen JP. Dapsone-induced peripheral neuropathy. Int J Dermatol. 1986;25:314–6.PubMedCrossRefGoogle Scholar
  2. Aine L, Reunala T, Maki M. Dental enamel defects in children with dermatitis herpetiformis. J Pediatr. 1991;118:572–4.PubMedCrossRefGoogle Scholar
  3. Aine L, Maki M, Reunala T. Coeliac-type dental enamel defects in patients with dermatitis herpetiformis. Acta Derm Venereol. 1992;72:25–7.PubMedGoogle Scholar
  4. Bardella MT, Fredella C, Trovato C, Ermacora E, Cavalli R, Saladino V, et al. Long-term remission in patients with dermatitis herpetiformis on a normal diet. Br J Dermatol. 2003;149:968–71.PubMedCrossRefGoogle Scholar
  5. Belmont A. Dapsone-induced nephrotic syndrome. JAMA. 1967;200:262–3.CrossRefGoogle Scholar
  6. Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis and clinical presentation. J Am Acad Dermatol. 2011a;64:1017–24.PubMedCrossRefGoogle Scholar
  7. Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol. 2011b;64:1027–33.PubMedCrossRefGoogle Scholar
  8. Bonciolini V, Bonciani D, Verdelli A, D’Errico A, Antiga E, Fabbri P. Newly described clinical and immunopathological feature of dermatitis herpetiformis. Clin Dev Immunol. 2012;967974. doi: 10.1155/2012/967974.
  9. Caproni M, Cardinali C, Renzi D, Calabró A, Fabbri P. Tissue transglutaminase antibody assessment in dermatitis herpetiformis. Br J Dermatol. 2001;1:196–7.CrossRefGoogle Scholar
  10. Caproni M, Antiga E, Fabbri P. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol. 2009;23:633–8.CrossRefGoogle Scholar
  11. Charlesworth EN, Backe JT, Garcia RL. Iodide-induced immunofluorescence in dermatitis herpetiformis. Arch Dermatol. 1976;11:555.CrossRefGoogle Scholar
  12. Cunningham MJ, Zone JJ. Thyroid abnormalities in dermatitis herpetiformis: prevalence of clinical thyroid disease and thyroid autoantibodies. Ann Intern Med. 1985;102:194–6.PubMedCrossRefGoogle Scholar
  13. Desai AM, Krishnan RS, Hsu S. Medical pearl: using tissue transglutaminase to diagnose dermatitis herpetiformis. J Am Acad Dermatol. 2005;53:867–8.PubMedCrossRefGoogle Scholar
  14. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997;3:797–801.PubMedCrossRefGoogle Scholar
  15. Dieterich W, Laag E, Bruckner-Tudermann L, Reunala T, Karpati S, Zagoni T, et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol. 1999;113:133–6.PubMedCrossRefGoogle Scholar
  16. Duhring LA. Dermatitis herpetiformis. JAMA. 1983;250:212–6.PubMedCrossRefGoogle Scholar
  17. Ermacora E, Prampolini L, Tribbia G, Pezzoli G, Gelmetti C, Cucchi G, et al. Long-term follow-up of dermatitis herpetiformis in children. J Am Acad Dermatol. 1986;15:24–30.PubMedCrossRefGoogle Scholar
  18. Flann S, Degiovanni C, Derrick EK, Munn E. Two cases of palmar petechiae as a presentation of dermatitis herpetiformis. Clin Exp Dermatol. 2010;35:206–8.PubMedCrossRefGoogle Scholar
  19. Fraser NG, Kerr NW, Donald D. Oral lesions in dermatitis herpetiformis. Br J Dermatol. 1973;89:439–50.PubMedCrossRefGoogle Scholar
  20. Fraser NG, Rennie AG, Donald D. Dermatitis herpetiformis and Sjögren’s syndrome. Br J Dermatol. 1979;100:213–5.PubMedCrossRefGoogle Scholar
  21. Fry L. Fine points in the management of dermatitis herpetiformis. Semin Dermatol. 1988;7:206–11.PubMedGoogle Scholar
  22. Fry L. Dermatitis herpetiformis. Bailleres Clin Gastroenterol. 1995;9:371–93.CrossRefGoogle Scholar
  23. Fry L. Dermatitis herpetiformis: problems, progress and prospects. Eur J Dermatol. 2002;12:523–31.PubMedGoogle Scholar
  24. Garioch JJ, Lewis HM, Sargent SA, Leonard JN, Fry L. 25 years’ experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol. 1994;131:541–5.PubMedCrossRefGoogle Scholar
  25. Hall III RP, Katz SI. Dermatitis herpetiformis. In: Wolff K, Goldsmith I, Katz SI, editors. Fitzpatrick’s dermatology in general medicine. 7th ed. New York: McGraw-Hill; 2007. p. 500–5.Google Scholar
  26. Hall III RP, Mickle CP. Dapsone. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. China: Elsevier; 2007. p. 239–57.Google Scholar
  27. Hall RP, Sanders ME, Duquesnoy RJ, Katz SI, Shaw S. Alternations in HLA-DP and HLA-DQ antigen frequency in patients with dermatitis herpetiformis. J Invest Dermatol. 1989;93:501–5.PubMedCrossRefGoogle Scholar
  28. Heinlin J, Knoppke B, Kohl E, Landthaler M, Karrer S. Dermatitis herpetiformis presenting as digital petechiae. Ped Dermatol. 2012;29:209–12.CrossRefGoogle Scholar
  29. Hervonen K, Karell K, Holopainen P, Collin P, Portanen J, Reunala T. Concordance of dermatitis herpetiformis and celiac disease in monozygous twins. J Invest Dermatol. 2000;115:990–3.PubMedCrossRefGoogle Scholar
  30. Hervonen K, Hakanen M, Kaukinen K, Collin P, Reunala T. First-degree relatives are frequently affected in coeliac disease and dermatitis herpetiformis. Scand J Gastroenterol. 2002;37:51–5.PubMedCrossRefGoogle Scholar
  31. Hervonen K, Viljamaa M, Collin P, Knip M, Reunala T. The occurrence of type 1 diabetes in patients with dermatitis herpetiformis and their first-degree relatives. Br J Dermatol. 2004;150:136–8.PubMedCrossRefGoogle Scholar
  32. Hervonen K, Vornanen M, Kautiainen H, Collin P, Reunala T. Lymphoma in patients with dermatitis herpetiformis and their first-degree relatives. Br J Dermatol. 2005;152:82–6.PubMedCrossRefGoogle Scholar
  33. Hitomi K. Transglutaminases in skin epidermis. Eur J Dermatol. 2005;15:313–9.PubMedGoogle Scholar
  34. Hofmann SC, Nashan D, Bruckner-Tuderman L. Petechiae on the fingertips as presenting symptom of dermatitis herpetiformis Duhring. J Eur Acad Dermatol. 2009;23:732–3.CrossRefGoogle Scholar
  35. Hörnsten P, Keisu M, Wiholm BE. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol. 1990;126:919–22.PubMedCrossRefGoogle Scholar
  36. Hull CM, Zone JJ. Dermatitis herpetiformis and linear IgA bullous dermatosis. In: Bolognia JL, Jorizzo JL, Schaffer JV, et al., editors. Dermatology, vol. 1. 3rd ed. Elsevier Limited; 2012. p. 491–500.Google Scholar
  37. Jaskowski TD, Hamblin T, Wilson AR, Hill HR, Book LS, Meyer LJ, et al. IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis and pediatric celiac disease. J Invest Dermatol. 2009;129:2728–30.PubMedCrossRefGoogle Scholar
  38. Jaskowski TD, Donaldson MR, Hull CM, Wilson AR, Hill HR, Zone JJ, et al. Novel screening assay performance in pediatric celiac disease and adult dermatitis herpetiformis. J Ped Gastroneterol Nutrit. 2010;51:19–23.CrossRefGoogle Scholar
  39. Johnson DA, Cattau Jr EL, Kuritsky JN, Zimmerman HJ. Liver involvement in the sulfone syndrome. Arch Int Med. 1986;146:875–7.CrossRefGoogle Scholar
  40. Jones SAV, Bhogal BS, Black MM. Fibrillar IgA deposition may be associated with atypical dermatitis herpetiformis – a report of two cases. J Eur Acad Dermatol. 1996;7:270–8.CrossRefGoogle Scholar
  41. Jukic LI, Marinovic B. Significance of immunofluorescence in the diagnosis of autoimmune bullous dermatoses. Clin Dermatol. 2011;29:389–97.PubMedCrossRefGoogle Scholar
  42. Junkins-Hopkins JM. Dermatitis herpetiformis: pearls and pitfalls in diagnosis and management. J Am Acad Dermatol. 2010;63:526–8.PubMedCrossRefGoogle Scholar
  43. Kaplan RP, Callen JP. Dermatitis herpetiformis: autoimmune disease associations. Clin Dermatol. 1991;9:347–60.PubMedCrossRefGoogle Scholar
  44. Kaplan AL, Lee LH, Hall III RP. Localized facial macules and vesicles. Arch Dermatol. 2004;140:353–8.PubMedCrossRefGoogle Scholar
  45. Karpati S. An exception within the group of autoimmune blistering diseases: dermatitis herpetiformis, the gluten-sensitive dermopathy. Dermatol Clin. 2011;29:436–8. doi: 10.1016/j.det.2011.03.019.CrossRefGoogle Scholar
  46. Karpati S. Dermatitis herpetiformis. Clin Dermatol. 2012;30:56–9.PubMedCrossRefGoogle Scholar
  47. Karpati S, Kosnai I, Verkasalo M, Kuitunen P, Simon Z, Koskimies S, et al. HLA antigens, jejunal morphology and associated diseases in children with dermatitis herpetiformis. Acta Paediatr Scand. 1986;75:297–301.PubMedCrossRefGoogle Scholar
  48. Kasparkiewicz M, Dähnrich C, Probst C, Komorowski L, Stöcker W, Schlumberger W, et al. Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides. J Am Acad Dermatol. 2012;66:583–8.CrossRefGoogle Scholar
  49. Kirby B, Keaveney A, Mrophy D, O’Donoghue D, Rogers S. Abnormal liver function tests induced by dapsone in a patient with dermatitis herpetiformis and primary sclerosing cholangitis. Br J Dermatol. 1999;141:172–3.PubMedCrossRefGoogle Scholar
  50. Ko CJ, Colegio OR, Moss JE, McNiff JM. Fibrillar IgA depositions in dermatitis herpetiformis – an underreported pattern with potential clinical significance. J Cut Pathol. 2010;37:475–7.CrossRefGoogle Scholar
  51. Koller WC, Gehlman LK, Malkinson FD, Davis FA. Dapsone-induced peripheral neuropathy. Arch Neurol. 1977;34:644–6.PubMedCrossRefGoogle Scholar
  52. Kumar V, Jarzabek-Chorzelska M, Sulej J, Rajadhyaksha M, Jablonska S. Tissue transglutaminase and endomysial antibodies – diagnostic markers of gluten-sensitive enteropathy in dermatitis herpetiformis. Clin Immunol. 2001;3:378–82.CrossRefGoogle Scholar
  53. Kuwakamo Y, Oyama N, Nakamura K, Kaneko F. A case of localized dermatitis herpetiformis on the face. J Am Acad Dermatol. 2008;58:59–60.CrossRefGoogle Scholar
  54. Lahteenoja H, Irjala K, Viander M, Vainio E, Toivanen A, Syrjänen S. Oral mucosa is frequently affected in patients with dermatitis herpetiformis. Arch Dermatol. 1998;134:756–8.PubMedCrossRefGoogle Scholar
  55. Lewis HM, Reunala T, Garioch JJ, Leonard JN, Fry JS, Collin P, et al. Protective effect of gluten-free diet against development of lymphoma in dermatitis herpetiformis. Br J Dermatol. 1996;135:363–7.PubMedCrossRefGoogle Scholar
  56. Llamazares JA, Gibson LE, Rogres RS. Clinical, pathologic and immunopathological features of dermatitis herpetiformis: review of the Mayo Clinic experience. Int J Dermatol. 2007;46:910–9.CrossRefGoogle Scholar
  57. Marks J, Shuster S, Watson A. Small bowel changes in dermatitis herpetiformis. Lancet. 1966;II:1280–2.CrossRefGoogle Scholar
  58. Matthias T, Pfeiffer S, Selmi C, Gershwin ME. Diagnostic challenges in celiac disease and the role of the tissue transglutaminase-neo-epitope. Clin Rev Aller Immunol. 2010;38:298–301.CrossRefGoogle Scholar
  59. Mc Kee PH, Calonje E, Granter SR. Inherited and autoimmune subepidermal blistering diseases. In: Mc Kee PH, Calonje E, Granter SR, editors. Pathology of the skin with clinical correlations. Boston: Elsevier Mosby; 2005. p. 81–139.Google Scholar
  60. McFadden JP, Leonard JN, Powles AV, Rutman AJ, Fry L. Sulphamethoxypyridazine for dermatitis herpeti-formis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol. 1989;121:759–62.Google Scholar
  61. Moi H. Incidence and prevalence of dermatitis herpetiformis in a county in central Sweden with comments on the course of the disease and IgA deposits as a diagnostic criterion. Acta Derm Venereol. 1984;64:144–50.PubMedGoogle Scholar
  62. Nicolas MO, Krause PK, Gibson LE, Murray JA. Dermatitis herpetiformis. Int J Dermatol. 2003;42:588–600.PubMedCrossRefGoogle Scholar
  63. Ohata C, Ishii N, Hamada T, Shimomura Y, Niizeki H, Dainichi T, et al. Distinct characteristics in Japanese dermatitis herpetiformis: a review of all 91 Japanese patients over the last 35 years. Clin Dev Immunol. 2012;2012:562168. doi: 10.1155/2012/562168. Epub 2012 Jun 12.CrossRefPubMedPubMedCentralGoogle Scholar
  64. Paek SY, Steinberg SM, Katz SI. Remission in dermatitis herpetiformis: a cohort study. Arch Dermatol. 2011;147:301–5.PubMedCrossRefGoogle Scholar
  65. Radoš J. Autoimmune blistering diseases: histologic meaning. Clin Dermatol. 2011;29:377–88.PubMedCrossRefGoogle Scholar
  66. Reunala TL. Dermatitis herpetiformis. Clin Dermatol. 2001;19:728–36.PubMedCrossRefGoogle Scholar
  67. Reunala T, Collin P. Diseases associated with dermatitis herpetiformis. Br J Dermatol. 1997;136:315–8.PubMedCrossRefGoogle Scholar
  68. Reunala TL, Lokki J. Dermatitis herpetiformis in Finland. Acta Derm Venereol. 1978;58:505–10.PubMedGoogle Scholar
  69. Reunala T, Salmi J, Karvonen J. Dermatitis herpetiformis and celiac disease associated with Addison’s disease. Arch Dermatol. 1987;123:930–2.PubMedCrossRefGoogle Scholar
  70. Rose C, Dietrich W, Brocker EB, Schuppan D, Zillikens D. Circulating antibodies to tissue transglutaminase differentiate patients with dermatitis herpetiformis from those with linear IgA dermatosis. J Am Acad Dermatol. 1999;41:957–61.PubMedCrossRefGoogle Scholar
  71. Rose C, Armbruster FP, Ruppert J, Igl BW, Zillikens D, Shimanovich I. Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermatol. 2009;61:39–43.PubMedCrossRefGoogle Scholar
  72. Rostom A, Murray A, Kagnoff MF. American gastroenterological association (AGA) institute technical review on the diagnosis and management of celiac disease. Gastroenterology. 2006;131:1981–2002.PubMedCrossRefGoogle Scholar
  73. Rutten A, Goos M. Palmoplantar purpura in dermatitis herpetiformis Duhring. Hautartz. 1989;40:640–3.Google Scholar
  74. Sachs JA, Awad J, McCloskey D, Navarrete C, Festenstein H, Elliot E, et al. Different HLA associated gene combinations contribute to susceptibility for coeliac disease and dermatitis herpetiformis. Gut. 1986;27:515–20.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Saito M, Böer A, Ishiko A, Nishikawa T. Atypical dermatitis herpetiformis: a Japanese case presents with initial lesions mimicking prurigo pigmentosa. Clin Exp Dermatol. 2006;31:290–1.PubMedCrossRefGoogle Scholar
  76. Samolitis NJ, Hull CM, Leiferman KM, Zone JJ. Dermatitis herpetiformis and partial IgA deficiency. J Am Acad Dermatol. 2006;54:206–9.CrossRefGoogle Scholar
  77. Sansaricq F, Stein SL, Petronic-Rosic V. Autoimmune bullous diseases in childhood. Clin Dermatol. 2012;30:114–27.PubMedCrossRefGoogle Scholar
  78. Sardy M, Karpati S, Merkl B, Paulsson M, Smyth N. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med. 2002;195:747–57.PubMedPubMedCentralCrossRefGoogle Scholar
  79. Shibahara M, Nanko H, Shimitzu M, Kanda N, Kubo M, Ikeda M, et al. Dermatitis herpetiformis in Japan: an update. Dermatology. 2002;204:37–42.PubMedCrossRefGoogle Scholar
  80. Smith JB, Tulloch JE, Meyer LJ, Zone JJ. The incidence and prevalence of dermatitis herpetiformis in Utah. Arch Dermatol. 1992;128:1608–10.PubMedCrossRefGoogle Scholar
  81. Spurkland A, Ingvarsson G, Falk ES, Knutsen I, Sollid LM, Thorsby E. Dermatitis herpetiformis and celiac disease are both primarily associated with HLA-DQ (α1*0501, β1*02) or the HLA-DQ (α1*03, β1*0302) heterodimers. Tissue Antigens. 1997;49:29–34.PubMedCrossRefGoogle Scholar
  82. Thomas III JR, Su WP. Concurrence of lupus erythematosus and dermatitis herpetiformis: a report of nine cases. Arch Dermatol. 1983;119:740–5.PubMedCrossRefGoogle Scholar
  83. Thrash B, Patel M, Shah KR, Boland CR, Menter A. Cutaneous manifestations of gastrointestinal disease. J Am Acad Dermatol. 2013;68:211.e1–33.CrossRefGoogle Scholar
  84. Van Heel DA, Franke L, Hunt KA, Gwilliam R, Zhernakova A, Inouye M, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL 21. Nat Genet. 2007;39:827–9.PubMedPubMedCentralCrossRefGoogle Scholar
  85. Willsteed E, Lee M, Wong LC, Cooper A. Sulfasalazine and dermatitis herpetiformis. Autralas J Dermatol. 2005;46:101–3.CrossRefGoogle Scholar
  86. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45:420–34.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Dermatology and VenereologyUniversity Hospital Center Zagreb, University of Zagreb School of MedicineZagrebCroatia

Personalised recommendations